In a groundbreaking initiative, Burjeel Holdings is joining forces with Caring Cross to establish advanced biomanufacturing facilities dedicated to chimeric antigen receptor (CAR)-T cell therapies in the United Arab Emirates (UAE). This collaboration aims to revolutionize the production and
INCOG, a contract development and manufacturing organization (CDMO), recently made a substantial investment to expand its capabilities in the sterile injectables sector. In February 2024, the company committed $75 million to install an Optima syringe and cartridge filling line, projected to be GMP
Recce Pharmaceuticals, a Sydney-based biotechnology company, has successfully raised A$15.8 million to advance its groundbreaking anti-infective drugs into Phase 3 trials. This funding was obtained through a combination of private placement and an entitlement offer. Recce's synthetic
Tango Therapeutics, a biotechnology company specializing in cancer treatments, has taken significant measures to address the challenging financial landscape. Recently, the company announced layoffs affecting approximately 20% of its workforce, a strategic move designed to extend its cash runway. As
The biopharmaceutical sector has witnessed significant changes in leadership roles within major Contract Development and Manufacturing Organizations (CDMOs), driving strategic growth and development. The appointment of seasoned leaders plays a crucial role in strengthening the research,
Artis Biosolutions' acquisition of Landmark Bio marks a strategic move designed to bolster cell and gene therapy (CGT) manufacturing capabilities. Landmark Bio, founded by Harvard University, MIT, Fujifilm Diosynth Biotechnologies, Alexandria Real Estate Equities, and Cytiva, has been a key
